Successful guselkumab treatment of a refractory psoriasis patient with Graves' disease: a case report

作者全名：Shao, Xinyi; Huang, Kun; Chen, Aijun; Liu, Chuan; Xiong, Jianxia; Pan, Yun; Chen, Xiaoli; Wang, Ping

作者地址：[Shao, Xinyi; Huang, Kun; Chen, Aijun; Liu, Chuan; Xiong, Jianxia; Pan, Yun; Chen, Xiaoli; Wang, Ping] Chongqing Med Univ, Dept Dermatol, Affiliated Hosp 1, Chongqing, Peoples R China; [Wang, Ping] Chongqing Med Univ, Dept Dermatol, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China

通信作者：Wang, P (通讯作者)，Chongqing Med Univ, Dept Dermatol, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.

来源：JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001207802400001

JCR分区：Q4

影响因子：1.4

年份：2024

卷号：52

期号：4

开始页：　

结束页：　

文献类型：Article

关键词：Guselkumab; refractory; psoriasis; Graves' disease; biological agent

摘要：Psoriasis is a chronic inflammatory skin disease. It is associated with many autoimmune diseases such as rheumatoid arthritis, Crohn's disease and thyroid diseases. Graves' disease (GD) is a common organ-specific autoimmune disease characterized by diffuse goitre and thyrotoxicosis. Management of psoriasis patients with GD is challenging. This current report presents the case of a 34-year-old female patient with refractory psoriasis with GD who was hospitalized for drug eruption and then experienced new-onset erythema and scaling following treatment with adalimumab and secukinumab. Despite the sequential move to phototherapy, tofacitinib and ustekinumab, the erythema and scaling continued unabated and exacerbated. Finally, switching to guselkumab resulted in the psoriasis lesions significantly improving. These findings suggest that guselkumab might be an effective treatment option for refractory psoriasis combined with GD.

基金机构：　

基金资助正文：